Page 224 - Haematologica Vol. 109 - July 2024

ARTICLE - Carfilzomib, thalidomide and dexamethasone (KTd) in RRMM S. Ninkovic et al.
Blood Adv. 2019;3(23):4095-4103.
10. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib,
lenalidomide, and dexamethasone for relapsed multiple
myeloma. N Engl J Med. 2015;372(2):142-152.
11. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib,
lenalidomide, and dexamethasone for multiple myeloma. N Engl
J Med. 2016;374(17):1621-1634.
12. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab,
lenalidomide, and dexamethasone for multiple myeloma. N Engl
J Med. 2016;375(14):1319-1331.
13. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
for relapsed or refractory multiple myeloma. N Engl J Med.
2015;373(7):621-631.
14. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and
dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38.
15. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
16. Kropff M, Baylon HG, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97(5):784-791.
17. Moreau P, Joshua D, Chng W-J, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31(1):115-122.
18. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
19. Dimopoulos M, Wang M, Maisnar V, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018;11(1):49.
20. Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177(3):404-413.
21. Weisel K, Mateos M-V, Gay F, et al. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup
analysis from ASPIRE and ENDEAVOR. Leukemia.
2021;35(6):1732-1744.
22. Avet-Loiseau H, Fonseca R, Siegel D, et al. Efficacy and safety
of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: subgroup analysis from the phase 3 atudy ASPIRE (NCT01080391). Blood. 2015;126(23):731.
23. Mateos M-V, Goldschmidt H, San-Miguel J, et al. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: a subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018;36(2):463-470.
24. Mellors PW, Binder M, Ketterling RP, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4(10):2236-2244.
25. Dimopoulos M, Siegel D, White DJ, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2019;133(2):147-155.
26. Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol. 2017;79(6):1067-1076.
27. Iida S, Watanabe T, Matsumoto M, et al. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: a phase 1/2 study. Cancer Sci. 2019;110(9):2924-2932.
28. Quach H, Yoon S-S, Kim K, et al. Carfilzomib use among patients with relapsed/refractory multiple myeloma in the Asia Pacific region: characteristics and outcomes by regimen from a prospective, real-world study. Blood. 2022;140(Suppl 1):4264-4266.
29. Dimopoulos MA, Moreau P, Iida S, et al. Outcomes for Asian patients with multiple myeloma receiving once- or twice- weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. Int J Hematol. 2019;110(4):466-473.
30. Moreau P, Mateos M-V, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953-964.
31. Eigbire-Molen O, Hermelin D, Blackall D. Carfilzomib-induced thrombotic microangiopathy: focus on pathogenesis. J Med Cases. 2022;13(6):274-280.
Haematologica | 109 July 2024
2238